We are live on ! Find out more
MDCX

Medicus Pharma
MDCX

0.1703 USD
-0.0003
0.18%
At close Updated Sep 18, 4:00 PM EDT
Pre-market
After hours
0.1715
+0.0012
0.7%
1 day
-0.18%
5 days
2.1%
1 month
-35.32%
3 months
-62.78%
6 months
-65.94%
Year to date
-89.36%
1 year
-92.99%
5 years
-93.57%
10 years
-93.57%
 

About: Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.

Employees: 16

Healthcare Drug Manufacturers - General

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 55%
Neutral 45%
Negative 0%
Positive
Proactive Investors
6 days ago
Medicus Pharma CEO on SkinJect and Pfizer partnership – ICYMI
Medicus Pharma (NASDAQ:MDCX) earlier this week outlined progress across its SkinJect program and a co-development and licensing opportunity with Pfizer, with CEO Raza Bokhari highlighting clinical, partnership and funding developments as the company sharpens its focus on precision oncology and capital-efficient drug development. Bokhari said final SkinJect results published on ClinicalTrials.gov had confirmed the 200-microgram patch as the dose to be taken forward into further registrational studies.
Medicus Pharma CEO on SkinJect and Pfizer partnership – ICYMI
Positive
Proactive Investors
8 days ago
Medicus Pharma reports positive Phase 2 data for SkinJect in skin cancer treatment
Medicus Pharma (NASDAQ:MDCX) said a completed Phase 2 study of its SkinJect therapy showed all 90 enrolled patients finished treatment without discontinuations, data the company says will guide its next-stage registrational trial in a rare genetic skin cancer syndrome. The randomized, double-blind, multicenter trial enrolled patients across 10 US investigative sites, comparing two dose levels of SkinJect against a device-only microneedle comparator.
Medicus Pharma reports positive Phase 2 data for SkinJect in skin cancer treatment
Neutral
GlobeNewsWire
8 days ago
Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose
CSR provides a clinical foundation for the Company's recently announced capital-efficient focus on FDA-authorized Gorlin Syndrome NDA-enabling development program while supporting partnership discussions to advance nodular Basal Cell Carcinoma CSR provides a clinical foundation for the Company's recently announced capital-efficient focus on FDA-authorized Gorlin Syndrome NDA-enabling development program while supporting partnership discussions to advance nodular Basal Cell Carcinoma
Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose
Positive
Proactive Investors
10 days ago
Medicus Pharma reorients around new cancer drug candidate, sharpens focus for other programs
Medicus Pharma (NASDAQ:MDCX) is repositioning itself as a precision oncology-led biotechnology company, centering its strategy on CD228V, a second-generation antibody-drug conjugate targeting CD228-expressing solid tumors, the company said Tuesday. CD228V is now the company's principal strategic priority, with initial development focused on establishing clinical proof-of-concept in a selected tumor population.
Medicus Pharma reorients around new cancer drug candidate, sharpens focus for other programs
Neutral
GlobeNewsWire
10 days ago
Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company
Company prioritizes CD228V precision oncology development in Melanoma while pursuing capital-efficient partnerships for SkinJect® and Teverelix® indications Company prioritizes CD228V precision oncology development in Melanoma while pursuing capital-efficient partnerships for SkinJect® and Teverelix® indications
Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company
Positive
Benzinga
15 days ago
Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion
Medicus Pharma Ltd. (NASDAQ:MDCX) secured on Wednesday an exclusive, sublicensable global license from Pfizer Inc. (NYSE:PFE) to develop, manufacture, and commercialize PF-08046031 (CD228V), an early clinical-stage antibody-drug conjugate targeting melanotransferrin.
Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion
Positive
Proactive Investors
1 month ago
Medicus Pharma advances pipeline during Q2 with key milestones
Medicus Pharma (NASDAQ:MDCX) has reported second quarter financial results and regulatory and clinical progress across its SkinJect and Teverelix programs, while raising about $40 million through equity and debt financing during the first half of 2026. The company said it received FDA “Study May Proceed” authorization for its registrational SkinJect study in patients with Gorlin Syndrome.
Medicus Pharma advances pipeline during Q2 with key milestones
Neutral
Accesswire
1 month ago
Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Company Highlights Significant Regulatory, Clinical and Strategic Progress Across SkinJect® and Teverelix® Programs and a Strengthened Financial Position Supporting Continued Pipeline Execution and Expansion PHILADELPHIA, PA / ACCESS Newswire / August 12, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today reported financial results for the three and six months ended June 30, 2026, and provided a corporate update highlighting significant regulatory, clinical and strategic achievements across its development portfolio.
Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Neutral
Proactive Investors
1 month ago
Medicus Pharma CMO to lead Antev's Teverelix clinical programme
Medicus Pharma (NASDAQ:MDCX) announced it has put its chief medical officer in charge of UK subsidiary Antev Limited, consolidating leadership of the Teverelix clinical programme ahead of regulatory, late-stage development and partnering work. Dr Faisal Mehmud will become Antev's chief executive on August 30, while retaining his positions as Medicus chief medical officer and co-chairman of the subsidiary.
Medicus Pharma CMO to lead Antev's Teverelix clinical programme
Neutral
GlobeNewsWire
1 month ago
Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom
Dr. Mehmud's appointment further aligns the scientific, clinical, regulatory and operational leadership of Antev Dr. Mehmud's appointment further aligns the scientific, clinical, regulatory and operational leadership of Antev
Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom
See News Rankings
Price charts implemented using Lightweight Charts™